The DOI matches its Crossref record.
CYP2C19 Polymorphism and Proton Pump Inhibitors
Open accessAbstract
Proton pump inhibitors such as omeprazole (esomeprazole), lansoprazole, pantoprazole and rabeprazole are eliminated by the hepatic route and the polymorphic CYP2C19 is mainly involved in their metabolism. In different populations three phenotypes have been identified: extensive metabolizers, poor metabolizers and individuals carrying one wild type and one mutant allele (het extensive metabolizers). Systemic exposure to the proton pump inhibitors as expressed by the AUC (area under the plasma level time profiles) is 5–12‐times higher in poor metabolizers than in extensive metabolizers. As the pharmacodynamic response (elevation of intragastric pH) to the proton pump inhibitors is related directly to their AUC, a much higher pH can be monitored over 24 hr in poor metabolizers than in extensive metabolizers. Furthermore, clinical efficacy of all proton pump inhibitors depend on maintaining intragastric pH above certain threshold levels and significantly higher eradication rates of Helicobacter pylori have been observed in patients of the poor metabolizers and het extensive metabolizers phenotype if compared to extensive metabolizers. Likewise, limited data suggest that proton pump inhibitors‐induced healing rates in gastro‐oesophageal reflux disease are apparently higher in poor metabolizers/het extensive metabolizers than in extensive metabolizers of CYP2C19. Therefore initial genotyping for this enzyme and higher dosage in extensive metabolizers is likely to improve the clinical efficacy of proton pump inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Since CYP2C19 contributes significantly to the metabolism of the PPIs omeprazole, lansoprazole, and pantoprazole and to minor extent to the metabolism of rabeprazole, pharmacokinetics, the PPI-induced increase in intragastric pH and treatment outcome depend on CYP2C19 genotype (Furuta et al., 1998; Klotz et al., 2004;…”
BackgroundSelf-citationPharmacokinetics and drug metabolism in the elderly
Klotz, U. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902722679 · Cited by 826
“Among the widely used proton pump inhibitors (PPIs), omeprazole represents the best probe for CYP2C19 (Klotz et al., 2004).”
BackgroundInfluentialSelf-citationSIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
Shi, S., & Klotz, U. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0538-y · Cited by 314
Self-citation
Metadata
- Authors
- Klotz, U., Schwab, M., & Treiber, G.
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2004-07
- Volume
- 95
- Issue
- 1
- Pages
- 2-8
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W1875488666
- Cited by
- 166
- References
- 0
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CYP2C19 Polymorphism and Proton Pump Inhibitors. https://app.cochat.ai/papers/10.1111/j.1600-0773.2004.pto950102.x
- The paper
- Klotz, U., Schwab, M., & Treiber, G. (2004). CYP2C19 Polymorphism and Proton Pump Inhibitors. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/j.1600-0773.2004.pto950102.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.